Molecular Subtypes Of Breast Cancer Associate With Response To Neoadjuvant Chemotherapy And Prognosis In Breast Cancer Patients

Objective:To investigate the correlation between breast cancer molecular subtypes with the response and outcome of breast cancer patients treated with neoadjuvant chemotherapy.Patients and Methods:162breast cancer patients treated with neoadjuvant chemotherapy were retrospectively analyzed in this study. Molecular subtypes were subdivided as Luminal A, Luminal B, HER-2positive and triple-negative subtype, basing on immunohistochemical results of estrogen receptor (ER), progesterone receptor (PR) and HER-2status. Correlation between response to neoadjuvant chemotherapy and prognosis with molecular subtypes was mainly estimated.Results:Among all162cases,61(37.7%) were Luminal A subtype,41(25.3%) were Luminal B subtype,27(16.6%) were HER-2positive subtype and33(20.4%) were triple-negative subtype. The effective rate of neoadjuvant chemotherapy in patients with triple-negative and HER-2positive subtype were81.5%and87.9%, respectively, which were significantly higher than that of patients with Luminal A subtype (odds ratio3.141,95%CI=1.030-9.577, P=0.044and5.162,95%CI=1.573-16.965, P=0.007). triple-negative and HER-2positive subtype patients had decreased disease-free survival (DFS) and overall survival (OS) compared with that of Luminal A subtype (P<0.050). Compared with hormonal receptors (HR) negative patients, hormonal receptors (HR) positive patients had significantly higher DFS and OS (P<0.05).Conclusion:Molecular subtype can predict the response of breast cancer patients treated with neoadjuvant chemotherapy. Compared with Luminal A subtype, patients with HER2positive or triple-negative subtype had increased effective rates but significantly worse survival.